Related Experiment Video

Updated: May 21, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia

Andrea Bonetto1, Tufan Aydogdu, Xiaoling Jin

  • 1Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

American Journal of Physiology. Endocrinology and Metabolism
|June 7, 2012
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) activation is a key driver of muscle wasting in cancer cachexia and other conditions. Inhibiting STAT3 can reduce muscle atrophy, suggesting it as a therapeutic target.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Cachexia involves metabolic dysregulation and significant loss of muscle and adipose tissue.
  • Interleukin-6 (IL-6) and related cytokines are linked to muscle wasting, but the precise mechanisms remain unclear.
  • The JAK/STAT3 pathway is activated by IL-6 family ligands and its role in skeletal muscle mass regulation is not well understood.

Purpose of the Study:

  • To investigate the role of the JAK/STAT3 pathway in regulating skeletal muscle mass during cachexia.
  • To determine if STAT3 activation is a common mechanism underlying muscle wasting in various catabolic conditions.
  • To evaluate STAT3 as a potential therapeutic target for preventing muscle loss in cachexia.

Main Methods:

  • Analysis of STAT3 phosphorylation, nuclear localization, and gene expression in cachectic models (C26 cancer cachexia, sterile sepsis).
  • In vivo and in vitro experiments using IL-6 stimulation in muscle cells and animal models.
  • Genetic and pharmacological inhibition of STAT3 signaling (constitutively active STAT3, dominant-negative STAT3, JAK/STAT3 inhibitors).

Main Results:

  • STAT3 activation was observed in skeletal muscle across different models of cachexia, including cancer and sepsis.
  • STAT3 activation was both necessary and sufficient for inducing muscle fiber atrophy and exacerbating cachexia.
  • Inhibition of STAT3 signaling, through pharmacological or genetic means, effectively reduced muscle atrophy.

Conclusions:

  • STAT3 is a central mediator of muscle wasting in cancer cachexia and other conditions characterized by high IL-6 family signaling.
  • Targeting the STAT3 pathway offers a promising therapeutic strategy for preserving skeletal muscle mass in cachectic patients.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...